Page 781 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 33 Hematopoietic Tumors 759

289. Sato M, Yamzaki J, Goto-Koshino Y, et al.: The prognostic signifi- 308. Treggiari E, Elliott JW, Baines SJ, et al.: Temozolomide alone or in
cance of minimal residual disease in the early phases of chemotherapy combination with doxorubicin as a rescue agent in 37 cases of canine
in dogs with high-grade B-cell lymphoma, Vet J 195:319–324, 2013. multicentric lymphoma, Vet Comp Oncol 16:194–201, 2018.
VetBooks.ir 290. Thilakaratne DN, Mayer MN, MacDonald VS, et al.: Clonality and 309. Alvarez FJ, Kisseberth WC, Gallant SL, et al.: Dexamethasone,
melphalan, actinomycin D, cytosine arabinoside (DMAC) proto-
phenotyping of canine lymphomas before chemotherapy and during
remission using polymerase chain reaction (PCR) on lymph node
cytologic smears and peripheral blood, Can Vet J 51:79–84, 2010. col for dogs with relapsed lymphoma, J Vet Intern Med 20:1178–
1183, 2006.
291. Valerius KD, Ogilvie GK, Fettman MJ, et al.: Comparison of the 310. Bannink EO, Sauerbrey ML, Mullins MN, et al.: Actinomycin D
effects of asparaginase administered subcutaneously versus intra- as rescue therapy in dogs with relapsed or resistant lymphoma: 49
muscularly for treatment of multicentric lymphoma in dogs receiv- cases (1999–2006), J Am Vet Med Assoc 233:446–451, 2008.
ing doxorubicin, J Am Vet Med Assoc 214:353–356, 1999. 311. Dervisis NG, Dominguez PA, Sarbu L, et al.: Efficacy of temo-
292. Valli VE, Jacobs RM, Norris A, et al.: The histologic classifica- zolomide or dacarbazine in combination with an anthracycline for
tion of 602 cases of feline lymphoproliferative disease using the rescue chemotherapy in dogs with lymphoma, J Am Vet Med Assoc
National Cancer Institute working formulation, J Vet Diagn Invest 231:563–569, 2007.
12:295–306, 2000. 312. Flory AB, Rassnick KM, Al-Sarraf R, et al.: Combination of CCNU
293. Yamazaki J, Baba K, Goto-Koshino Y, et al.: Quantitative assess- and DTIC chemotherapy for treatment of resistant lymphoma in
ment of minimal residual disease (MRD) in canine lymphoma by dogs, J Vet Intern Med 22:164–171, 2008.
using real-time polymerase chain reaction, Vet Immunol Immuno- 313. Griessmayr PC, Payne SE, Winter JE, et al.: Dacarbazine as single-
pathol 126:321–331, 2008. agent therapy for relapsed lymphoma in dogs, J Vet Intern Med
294. Nielsen L, Toft N, Eckersall PD, et al.: Serum C-reactive protein 23:1227–1231, 2009.
concentration as an indicator of remission status in dogs with mul- 314. Moore AS, London CA, Wood CA, et al.: Lomustine (CCNU)
ticentric lymphoma, J Vet Intern Med 21:1231–1236, 2007. for the treatment of resistant lymphoma in dogs, J Vet Intern Med
295. Ito D, Endicott MM, Jubala CM, et al.: A tumor-related lymphoid 13:395–398, 1999.
progenitor population supports hierarchical tumor organization in 315. Moore AS, Ogilvie GK, Ruslander D, et al.: Evaluation of mitoxan-
canine B-cell lymphoma, J Vet Intern Med 25:890–896, 2011. trone for the treatment of lymphoma in dogs, J Am Vet Med Assoc
296. Tomiyasu H, Tsujimoto H: Comparative aspects of molecular 204:1903–1905, 1994.
mechanisms of drug resistance through ABC transporters and other 316. Moore AS, Ogilvie GK, Vail DM: Actinomycin D for reinduction
related molecules in canine lymphoma, Vet Sci 2:185–205, 2015. of remission in dogs with resistant lymphoma, J Vet Intern Med
297. Zandvliet M, Teske E: Mechanisms of drug resistance in veterinary 8:343–344, 1994.
oncology- a review with an emphasis on canine lymphoma, Vet Sci 317. Northrup NC, Gieger TL, Kosarek CE, et al.: Mechlorethamine,
2:150–184, 2015. procarbazine and prednisone for the treatment of resistant lym-
298. Zandvliet M, Teske E, Schrickx JA, et al.: A longitudinal study of phoma in dogs, Vet Comp Oncol 7:38–44, 2009.
ABC transporter expression in canine multicentric lymphoma, Vet 318. Rassnick KM, Mauldin GE, Al-Sarraf R, et al.: MOPP chemo-
J 205:263–271, 2015. therapy for treatment of resistant lymphoma in dogs: a retrospec-
299. Lee JJ, Hughes CS, Fine RL, et al.: P-glycoprotein expression in tive study of 117 cases (1989-2000), J Vet Intern Med 16:576–580,
canine lymphoma: a relevant, intermediate model of multidrug 2002.
resistance, Cancer 77:1892–1898, 1996. 319. Saba CF, Hafeman SD, Vail DM, et al.: Combination chemother-
300. Flory AB, Rassnick KM, Erb HN, et al.: Evaluation of factors asso- apy with continuous L-asparaginase, lomustine, and prednisone for
ciated with second remission in dogs with lymphoma undergoing relapsed canine lymphoma, J Vet Intern Med 23:1058–1063, 2009.
retreatment with a cyclophosphamide, doxorubicin, vincristine, 320. Saba CF, Thamm DH, Vail DM: Combination chemotherapy with
and prednisone chemotherapy protocol: 95 cases (2000-2007), L-asparaginase, lomustine, and prednisone for relapsed or refrac-
J Am Vet Med Assoc 238:501–506, 2011. tory canine lymphoma, J Vet Intern Med 21:127–132, 2007.
301. Back AR, Schleis SE, Smrkovski OA, et al.: Mechlorethamine, vin- 321. Impellizeri JA, Howell K, McKeever KP, et al.: The role of ritux-
cristine, melphalan and prednisone (MOMP) for the treatment of imab in the treatment of canine lymphoma: an ex vivo evaluation,
relapsed lymphoma in dogs, Vet Comp Oncol 13:398–408, 2015. Vet J 171:556–558, 2006.
302. Fahey CE, Milner RJ, Barabas K, et al.: Evaluation of the Univer- 322. Jubala CM, Wojcieszyn JW, Valli VE, et al.: CD20 expression in
sity of Florida lomustine, vincristine, procarbazine, and prednisone normal canine B cells and in canine non-Hodgkin lymphoma, Vet
chemotherapy protocol for the treatment of relapsed lymphoma Pathol 42:468–476, 2005.
in dogs: 33 cases (2003-2009), J Am Vet Med Assoc 239:209–215, 323. Rue SM, Eckelman BP, Efe JA, et al.: Identification of a candidate
2011. therapeutic antibody for treatment of canine B-cell lymphoma, Vet
303. Gillem J, Giuffrida M, Krick E: Efficacy and toxicity of carboplatin Immunol Immunopathol 164:148–159, 2015.
and cytarabine chemotherapy for dogs with relapsed or refractory 324. Ito D, Brewer S, Modiano JF, et al.: Development of a novel anti-
lymphoma (2000-2013), Vet Comp Oncol 15:400–410, 2017. canine CD20 monoclonal antibody with diagnostic and therapeu-
304. Lenz JA, Robat CS, Stein TJ: Vinblastine as a second rescue for the tic potential, Leuk Lymphoma 56:219–225, 2015.
treatment of canine multicentric lymphoma in 39 cases (2005 to 325. Jain S, Aresu L, Comazzi S, et al.: The development of a recombi-
2014), J Small Anim Pract 57:429–434, 2016. nant scFv monoclonal antibody targeting canine CD20 for use in
305. Mastromauro ML, Suter SE, Hauck ML, et al.: Oral melphalan comparative medicine, PLoS One 11:e0148366, 2016.
for the treatment of relapsed canine lymphoma, Vet Comp Oncol 326. Weiskopf K, Anderson KL, Ito D, et al.: Eradication of canine
16:E123–E129, 2018. diffuse large B-Cell lymphoma in a murine xenograft model with
306. Parsons-Doherty M, Poirier VJ, Monteith G: The efficacy and CD47 blockade and anti-CD20, Cancer Immunol Res 4:1072–
adverse event profile of dexamethasone, melphalan, actinomycin 1087, 2016.
D, and cytosine arabinoside (DMAC) chemotherapy in relapsed 327. Crow SE, Theilen GH, Benjaminini E, et al.: Chemoimmunother-
canine lymphoma, Can Vet J 55:175–180, 2014. apy for canine lymphosarcoma, Cancer 40:2102–2108, 1977.
307. Tanis JB, Mason SL, Maddox TW, et al.: Evaluation of a multi- 328. Weller RE, Theilen GH, Madewell BR, et al.: Chemoimmunother-
agent chemotherapy protocol combining lomustine, procarbazine apy for canine lymphosarcoma: a prospective evaluation of specific
and prednisolone (LPP) for the treatment of relapsed canine non- and nonspecific immunomodulation, Am J Vet Res 1980(41):516–
Hodgkin high-grade lymphomas, Vet Comp Oncol, 2018. https:// 521, 1980.
doi.org/10.1111/vco.12387. epub ahead of print.